Michael S. Weiss Esq.
Net Worth
Last updated:
What is Michael S. Weiss Esq. net worth?
The estimated net worth of Mr. Michael S. Weiss Esq. is at least $484,297,970 as of 11 Aug 2023. He owns shares worth $449,079,583 as insider, has earned $1,282,527 from insider trading and has received compensation worth at least $33,935,860 in companies like TG Therapeutics, Inc., Fortress Biotech, Inc., Fortress Biotech, Inc. etc.
What is the salary of Michael S. Weiss Esq.?
Mr. Michael S. Weiss Esq. salary is $1,630,000 per year as Chairman, Chief Executive Officer & Pres in TG Therapeutics, Inc.. He also receives $576,630 as Vice Chairman & Executive Vice Chairman of Strategic Devel. in Fortress Biotech, Inc. and salaries from other companies.
How old is Michael S. Weiss Esq.?
Mr. Michael S. Weiss Esq. is 59 years old, born in 1966.
What stocks does Michael S. Weiss Esq. currently own?
As insider, Mr. Michael S. Weiss Esq. owns shares in 3 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIOP) | Vice Chairman & Executive Vice Chairman of Strategic Devel. | 14,752,034 | $7.57 | $111,672,897 |
| TG Therapeutics, Inc. (TGTX) | Chairman, Chief Executive Officer & Pres | 12,073,021 | $27.92 | $337,078,746 |
| Fortress Biotech, Inc. (FBIO) | Vice Chairman & Executive Vice Chairman of Strategic Devel. | 147,058 | $2.23 | $327,939 |
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
What does TG Therapeutics, Inc. do?
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
Michael S. Weiss Esq. insider trading
TG Therapeutics, Inc.
Mr. Michael S. Weiss Esq. has made 3 insider trades between 2012-2023, according to the Form 4 filled with the SEC. Most recently he purchased 100,000 units of TGTX stock worth $1,013,000 on 11 Aug 2023.
The largest trade he's ever made was exercising 210,618 units of TGTX stock on 16 Dec 2014. As of 11 Aug 2023 he still owns at least 12,073,021 units of TGTX stock.
Fortress Biotech, Inc.
TG Therapeutics key executives
TG Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Mr. Michael S. Weiss Esq. (59) Chairman, Chief Executive Officer & Pres
- Mr. Sean A. Power CPA, CPA (43) Chief Financial Officer, Corporation Sec. & Treasurer